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Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency has been associated with
acute psychosis, catatonic schizophrenia, and bipolar disorders by previous inconclusive reports. A
particularly disproportionate rate of enzyme deficiency was found in manic schizoaffective patients
from 662 lithium patients surveyed in Sardinia. The purpose of this study was to describe clinical
characteristics which may be potentially associated with G6PD deficiency.
Methods: Characteristics of episodes, course of illness, family pattern of illness, laboratory tests,
and treatment response of 29 G6PD-deficient subjects with a Research Diagnostic Criteria
diagnosis of manic schizoaffective disorder were abstracted from available records.
Results: The most peculiar pattern was that of acute recurrent psychotic manic episodes, mostly
characterized by loosening of associations, agitation, catatonic symptoms, and/or transient
confusion, concurrent hyperbilirubinemia, positive psychiatric family history, and partial response
to long-term lithium treatment.
Conclusions: A relationship between psychiatric disorder and G6PD deficiency is to be searched
in the bipolar spectrum, particularly among patients with a history of acute episodes with psychotic
and/or catatonic symptoms or with transient confusion.
Background
Glucose-6-phosphate dehydrogenase (G6PD) is a
cytosolic enzyme whose main function is to produce
NADPH, a key electron donor in the defense against oxi-
dizing agents and in reductive biosynthetic reactions [1].
More than 100 missense mutations in the human X-
linked gene encoding G6PD are known to date. The main
clinical consequence of these mutations is an enzyme
deficiency associated with acute hemolytic anemia, trig-
gered by fava beans, drugs, and some other sources of
stress [2]. G6PD deficiency has become common in many
populations as a result of malaria selection and it has been
estimated that 200 million people around the world are
G6PD deficient, including about 11% of Afro-Americans
and 62% of Kurdish Jews. Rates in southern Sardinia
range from 15 to 30% [3].
In the early 1980s, we used G6PD deficiency as a tradi-
tional X-chromosome marker in a linkage study of manic-
depressive illness [4]. Subsequent to this date, we started
a systematic survey of G6PD activity in outpatients admit-
ted to our Department, which is one of the reference cent-
ers for the management of lithium and related treatments
in southern Sardinia. In an account regarding 662 consec-
utive outpatients diagnosed according to modified
Research Diagnostic Criteria (RDC), we reported excessive
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proportions of subjects with enzyme deficiency in bipolar
compared with non-bipolar subgroups [5]. The greatest
contribution to the bipolar/non-bipolar distinction was
provided by "atypical" disorders, such as bipolar II and
manic schizoaffective disorder. The latter warranted par-
ticular attention because, while it is diagnosed in one
fourth of the overall population of outpatients followed at
our department, it was excessively represented in the sub-
group of G6PD-deficient patients (38%), particularly in
males (47%). In this report, clinical characteristics, course
of illness, family pattern of illness, laboratory tests, and
treatment response of G6PD-deficient subjects with a
diagnosis of manic schizoaffective disorder are described.
The results are discussed in the context of previous studies
that had already investigated potential relationships
between G6PD deficiency and psychoses [6–10].
Methods
Out of 662 subjects from a previous study [5], 29 unre-
lated subjects (5 women, 24 men) were selected based on
both severe G6PD deficiency and a RDC diagnosis of
manic schizoaffective disorder. All subjects were patients
registered at the lithium clinics, Department of Neuro-
sciences, University of Cagliari, between 1976 and 1999
and gave informed consent to participate in the study.
Detailed information was obtained from the patient and
from other available sources (such as relatives and refer-
ring clinicians) concerning demographic characteristics
and lifetime medical and psychiatric history. Moreover,
all available records regarding hospitalizations were
examined. Family history was also systematically col-
lected from the patient and from informative relatives.
G6PD activity was established using quantitative assays
on erythrocytes [11] or whole blood samples [12].
Patients included in this study were those with enzyme
activity close to zero, i.e. hemizygous men and women in
the homozygous range. Patients who attended the depart-
ment between 1993 and 1999 were also genotyped for the
G6PD-Mediterranean (G6PD-Med) mutation, which is
responsible for the majority of severe enzyme deficiency
in Sardinia [13].
Results
Demographic and clinical data regarding the 29 subjects
included in this study are shown in Table 1. Some charac-
teristics of index episodes abstracted from available hospi-
tal charts are shown in Table 2. Hospital diagnoses varied
greatly and reflected criteria used in Italy over the last
three decades. However, all patients shared RDC manic
schizoaffective diagnosis on revaluation, based, besides
on the common cluster of mania (i.e. elevated or expan-
sive mood, decreased need for sleep, hyperactivity, and
inflated self-esteem), on the presence of mood-incongru-
ent delusions (N = 18) (persecutory delusion or delusion
of being influenced or of thought broadcasting) and/or
loosening of associations (N = 12). Grandiose delusions
were reported in 11 cases. Religious, philosophical, scien-
tific, or magical themes were manifested by 12 patients.
Hallucinations were reported in 10 cases, but were not a
prominent characteristic. Involuntary hospitalization was
often required, mainly due to negativism, mutism or stu-
por (N = 11), or psychomotor agitation (N = 9). Several
patients (N = 7) manifested transient confusion.
The onset of episodes was invariably acute, ranging from
a few days to a few weeks. A substantial proportion of
patients showed abnormalities in routine laboratory tests
performed on admission to the hospital. A common pat-
tern (80% of cases) was characterized by mild hyperbiliru-
binemia (1–2.5 mg/dl) and/or urobilinogenuria (1–3
Ehrlich Units %), which returned to normal ranges when
checked a few days later. An additional frequent finding
(80% of cases) was a transitory low serum cholesterol
concentration (lower than 160 mg/dl). Ketonuria and
proteinuria were evidenced in three cases characterized by
catatonic features. Psychotic and manic symptoms sub-
sided in the majority of patients within a few weeks after
treatment with neuroleptics. Where necessary, a combina-
tion with benzodiazepines and/or lithium was adminis-
tered. In six cases, a few days of ECT achieved a successful
outcome. The course of illness was recurrent. The majority
of patients (90%) had been hospitalized at least once.
Depressive episodes, if any, were generally rarer or milder
than manic ones. Median duration of follow-up after
onset was 13 years. The long-term prophylactic effective-
ness of lithium treatment was rarely complete, often
Table 1: Characteristics of 29 G6PD-deficient manic schizoaffective patients
Gender 25 males, 4 females
Median age at onset 22 years
Median time between onset and starting lithium 5 years
Median time on lithium 6 years
Median number of manic episodes prior to lithium 2Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/6
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requiring combined treatment with antipsychotics or
other mood-stabilizers. However, recurrences during lith-
ium were milder than previous episodes and new hospi-
talizations were generally required only in patients who
were not compliant or had abandoned lithium treatment.
A substantial proportion of men also abused alcohol.
Many patients had a history of favism-related hemoglob-
inuric jaundice during childhood. The majority of
patients (64%) had a first-degree relative suffering from
psychiatric illness.
Discussion
This description of psychotic mania in a substantial pro-
portion of G6PD-deficient subjects attending our depart-
ment is to be discussed in the context of existing literature.
The role of G6PD deficiency in psychiatric disorders has
not been definitely established, studies varying from
reports of acute psychotic cases [6,7] to surveys of enzyme
activity in hospitalized populations [8–10,14]. G6PD
deficiency was also used as a traditional X-chromosome
marker in linkage studies [4,15–17]. The first study dates
back to 1962, when Dern et al [6] reported a not-other-
wise-described temporary psychosis during primaquine
administration in two G6PD-deficient subjects several
weeks after the subsidence of acute hemolytic anemia.
In 1976, Nasr reported two consecutive acute psychotic
episodes in a young Afro-American woman [7]. An
abstract of the description of the latter case is worthy of
mention: "She was in good mental health until one week
prior to admission, when she started to become irritable
and insomniac and heard voices telling her that people
were going to kill her. On mental status examination, she
was staring at the wall. Her mood was depressed and her
affect inappropriate. She admitted to auditory hallucina-
tions and ideas of reference and persecution. She was
alternately oriented and disoriented to place, person, and
time. It was assumed that she was suffering from an acute
paranoid psychosis. The routine laboratory work revealed
a hemoglobin level of 11.1 g/dl; a hematocrit reading of
34.6%, and a total bilirubin value of 1.7 mg/dl. These
findings suggested a hemolytic process. On her second
admission, she was found to be confused, agitated, and
disoriented; had auditory and visual hallucinations; and
manifested more bizarre behavior, like barking and pac-
ing the hall nude with a lampshade on her head. She had
a G6PD level in the homozygote-deficient range. She
Table 2: Characteristics of index episodes requiring hospitalization in 21 patients with available records
Age/Gender Hospital diagnosis Delusions Hallucinations Loosening of 
Associations
Additional Symptoms
66/F Manic-depressive illness Unspecified + Mutism, Confusion
23/F Mixed psychosis Persecutory + Agitation, Confusion
17/F Dissociative syndrome Thought broadcasting + Agitation, Posturing, 
Rigidity
29/F Brief reactive psychosis Thought broadcasting, Guilt
27/M Dissociative syndrome Grandiose, Scientific + Agitation
29/M Dissociated mania Religious, Magic + Agitation
32/M Psychomotor agitation Grandiose, Persecutory, Religious + + Agitation
35/M Manic-depressive psychosis Persecutory, Grandiose, Religious +
22/M Schizoid disorder Grandiose, Persecutory Stupor, Negativism, 
Confusion
34/M Confusional episode Being influenced, Grandiose + Confusion
20/M Acute delusional psychosis Grandiose, Persecutory + Agitation, Confusion
27/M Dissociative syndrome Religious, Grandiose + + Agitation
48/M Confusional episode Being influenced + Mutism, Confusion
40/M Manic-depressive psychosis Being influenced Blocking of speech
22/M Paranoid syndrome Grandiose, Scientific Confusion, Posturing
44/M Dissociative syndrome Grandiose, Persecutory + Stupor, Negativism
27/M Borderline syndrome Religious, Scientific + + Agitation
37/M Manic bipolar disorder Religious, Grandiose, Persecutory Mutism
39/M Manic bipolar disorder Grandiose, Persecutory + Agitation, Mutism, 
Posturing
47/M Mixed psychosis Persecutory, Jealousy + Stereotypies, Posturing, 
Negativism
21/M Psychotic mania Religious, Persecutory + +
Note: Hospital diagnoses were based on various criteria used in Italy over the last three decades. In particular, the term dissociative syndrome 
refers to loosening of association, and is not related to DSM-IV dissociative disorders.Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/6
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admitted to having eaten "funny Italian beans" two days
before the onset of her first illness." The author com-
mented: "the excellent recovery of this patient, the
absence of any family history of mental illness, the
absence of clear stressful life events leading to her psycho-
sis, and the presence of G6PD deficiency with suggestive
evidence of hemolysis led to the possibility of an organic
delirium as opposed to an acute paranoid schizophrenia".
Despite a different diagnosis and lack of clear manic
symptoms, there are striking similarities between the lat-
ter case and the majority of cases described here. Conceiv-
ably, hospital diagnoses (Table 2) have varied according
to the prominence of different "atypical" symptoms dur-
ing the index episode (e.g. persecutory delusion, loosen-
ing of associations, or confusion) as well as to the prior
course of illness (first episode as opposed to recurrence).
The ascertainment of patients from lithium clinics might
have led to a selection of patients with manic features,
recurrent episodes, or a bipolar course. However, the
excessive rate of RDC schizoaffective diagnoses among
G6PD deficient patients is consistent with the hypothesis
that this enzyme deficiency could confer greater severity to
manic episodes. In this series of patients, the most pecu-
liar picture resembles second and third stages of mania
according to Carlson and Goodwin [18]. The presence of
catatonic features and/or confusion also recalls delirious
mania as described in the past by Bell [19] and more
recently by Bond [20] and Fink [21]. Bond treated his
patients with haloperidol and lithium [20], while Fink
[21] opted for ECT especially when an underlying sys-
temic illness was suspected. Similar treatments were used
in patients from this series.
With regard to laboratory findings, data from available
hospital charts are suggestive of a transient metabolic dis-
order on admission. An association of excitement, delu-
sional thoughts, restlessness and confusion is known to
occur in medical conditions including toxic and meta-
bolic disorders. The most peculiar findings in a substan-
tial proportion of our G6PD-deficient subjects suffering
from acute psychotic mania were transitory hyperbiliru-
binemia and/or hyperurobilinogenuria, the causes of
which are difficult to identify retrospectively. We have
already described elsewhere two men from this sample
whose psychotic episodes were possibly associated with
hemolysis after ingestion of fava beans [22]. In an addi-
tional patient, onset of illness was associated with three
consecutive hospitalizations in the following order:
favism-related hemolysis, appendectomy, and psychosis.
In the remaining cases, hyperbilirubinemia was generally
mild and no overt signs of hemolysis, such as jaundice or
icteric sclerae, were reported. It is known that hyperbiliru-
binemia can have serious CNS consequences. One of the
latter is kernicterus in newborns, that has also been
reported in association with G6PD deficiency [2]. In this
case, however, the cause of jaundice is not entirely clear,
since hemolysis does not seem to have a major role. One
possibility is that the enzyme deficiency in the liver is suf-
ficiently severe to impair the catabolism of bilirubin.
Another example of potentially relevant non-erythrocyte
enzyme deficiency is found in hepatitis. In fact, alarming
hyperbilirubinemia may be found in the presence of
G6PD deficiency, even in adults [2]. The relevance of
bilirubin in these cases of psychotic mania cannot be
established, but it may be of interest to mention that
bilirubin has been suggested to play a role in hepatic
encephalopathy presenting as delirium and mania [23].
Moreover, an excess of idiopathic hyperbilirubinemia has
recently been reported in patients hospitalized for schizo-
phrenic psychosis [24,25], as the possible consequence of
increased vulnerability of red cell membranes and/or the
common polymorphism of the glucuronyl tranferase gene
(Gilbert's syndrome).
Hypocholesterolemia, which was often observed in
patients from this study, might be merely related to
neglect of nutritional needs during restless psychotic
mania, even though lowering of cholesterol levels has also
been reported after primaquine-induced hemolysis [26].
Whatever the role of hyperbilirubinemia and low choles-
terol concentrations, another potential mechanism in
G6PD-related psychoses may be an enzyme deficiency in
the CNS. There are no data concerning the CNS expres-
sion of G6PD mutations, but it is known that the brain is
one of the organs with the highest activity of G6PD in nor-
mal humans [27]. Interestingly, the activity of the hexose
monophosphate shunt, whose first step is catalyzed by
G6PD, can be stimulated in the brain by monoamine
transmitters, perhaps in relation with the detoxication of
monoamine-oxidase-dependent metabolites [28,29].
With regard to catatonic features, Dern et al [8] had
already raised the hypothesis of a potential role of G6PD
deficiency, even though the context was that of schizo-
phrenia subtypes. Their hypothesis was based on results
from a survey of 351 Afro-American patients hospitalized
for schizophrenia for longer than 8 months in Illinois.
G6PD deficiency was significantly in excess in the sub-
groups of both sexes classified as catatonic in comparison
to paranoid, especially in early onset cases. A replication
study of 562 men and 235 women hospitalized in New
York State could not confirm or deny previous findings
[9]. G6PD-deficiency rates were in excess in catatonic
compared with paranoid subtypes in males from four hos-
pitals, but the results were in the opposite direction at the
fifth hospital. A nonsignificant excess in the catatonic sub-
type was also reported in females when the lowest 10%
enzyme activity was analyzed. In a third study, no cata-
tonic/paranoid differences were found in 783 Afro-Amer-Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/6
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ican men hospitalized for schizophrenia in Alabama [10].
In view of such inconsistent results, the hypothesis of a
role of G6PD deficiency in catatonic schizophrenia was
abandoned. It was concluded that the discrepancies were
probably due to unreliability of subcategories of schizo-
phrenia as well as to the choice of samples of chronic
patients as opposed to the acute hemolysis-related psy-
chosis that had prompted the initial survey [6,8]. How-
ever, assuming that positive data were real despite
difficulties in replication, one might speculate as to poten-
tial relationships between catatonic schizophrenia as
diagnosed in the 1960s and psychotic mania with cata-
tonic features of our present-day patients. In fact, it is
known that catatonia was classified only as a subtype of
schizophrenia until DSM-III, and only recently has it been
recognized as a frequent manifestation of affective
disorder.
Whatever the relevance of catatonic features, over the last
two decades the interest in potential behavioral effects of
G6PD deficiency has been addressed to bipolar disorders.
In 1982, Nasr et al [14] reported a trend for increased pro-
portions of enzyme deficiency in bipolar patients from a
population of 104 psychiatric patients hospitalized in Illi-
nois. Similarly, as mentioned above, our survey of 662
Sardinian outpatients revealed excessive rates of G6PD
deficiency in bipolar compared to nonbipolar patients
[5]. The three-fold variation was consistent with the
hypothesis of G6PD deficiency as a susceptibility factor to
mania/hypomania in geographical areas with high inci-
dence. Our hypothesis was discussed in view of historical
pedigrees in the genetics of bipolar disorder, which used
G6PD deficiency as a marker in studies supporting the
once popular X-linkage hypothesis. We commented that
association with the marker itself rather than linkage with
a close gene might have played a role, since 12 out of 12
bipolar members in those pedigrees were G6PD deficient
[15–17].
The degree of contribution of cases with psychotic mania
to those pedigrees is not known, as clinical details were
not provided. Description of peculiar features, such as
psychotic symptoms or concurrence of medical condi-
tions, is currently being encouraged in psychiatric genetic
studies, and might provide useful clues [30,31]. We have
already reported that RDC manic schizoaffective disorder
clusters in families of our patients, and suggested G6PD
deficiency as one potential susceptibility factor [32]. In
published pedigrees with G6PD deficiency [15–17], since
the presence of psychotic features was not specified, the
only inferable clinical peculiarity was the tendency
towards a less severe phenotype (i.e. unipolar depression)
in heterozygotes compared to hemizygotes or homozy-
gotes, which is consistent with an X-linked condition.
In attempts at confirming the hypothesis of X-linked
transmission of affective disorder in pedigrees segregating
for G6PD deficiency, we have studied parents of 274 bipo-
lar probands, including 99 with a RDC diagnosis of manic
schizoaffective disorder [33]. The results were as expected,
because a significant excess of affective disorders in moth-
ers of hemizygotes for the G6PD-Mediterranean mutation
was found. The explanation may be that of a susceptibility
gene in linkage disequilibrium with the G6PD gene on the
Xq28 chromosome or of a direct role of G6PD deficiency
itself.
Conclusions
Based on previous reports of acute psychosis [6,7], surveys
of enzyme activity in psychiatric samples [5,14], genetic
linkage/association studies [4,15–17,33], and on the
series of cases described here, a relationship between psy-
chiatric disorder and G6PD deficiency should be searched
in the bipolar spectrum, particularly among patients with
a history of acute episodes with psychotic and/or cata-
tonic symptoms or with transient confusion.
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